SCHEMBL9967390

SCHEMBL9967390

Cc1cccc(C(=O)Nc2ccc(C)c(Nc3c(-c4cc(NCCN5CCN(C)CC5)ncn4)cnn3C)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 8/20 0.56
LYN P07948 8/20 0.56
SRC P12931 8/20 0.56
KDR P35968 7/20 0.56
INSR P06213 6/20 0.56
HCK P08631 6/20 0.54
BRAF P15056 8/20 0.47
MAPK14 Q16539 4/20 0.45
KIT P10721 5/20 0.44
ABL1 P00519 3/20 0.44
ABL2 P42684 3/20 0.44
RAF1 P04049 5/20 0.44
ARAF P10398 4/20 0.44
CSF1R P07333 4/20 0.42
EGFR P00533 2/20 0.42
ERBB2 P04626 2/20 0.42
FYN P06241 2/20 0.42
PDGFRB P09619 2/20 0.42
FGR P09769 2/20 0.42
BCR P11274 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9967391 0.93 MAPK14 (0.52) LCKLYNSRCKDRINSR
SCHEMBL3584384 0.91 LCK (0.66) LCKLYNSRCKDRINSR
SCHEMBL9967393 0.86 INSR (0.57) LCKLYNSRCKDRINSR
SCHEMBL3591659 0.84 LCK (0.60) LCKLYNSRCKDRINSR
SCHEMBL9967389 0.84 KDR (0.47) LCKLYNSRCKDRINSR
SCHEMBL9967394 0.79 MAPK14 (0.53) LCKLYNSRCKDRINSR
SCHEMBL3827237 0.79 KDR (0.66) LCKLYNSRCKDRINSR
SCHEMBL3596597 0.78 KDR (0.66) LCKLYNSRCKDRINSR
SCHEMBL9967406 0.75 MAPK14 (0.56) LCKLYNSRCKDRINSR
SCHEMBL3822873 0.75 KDR (0.66) LCKLYNSRCKDRINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-8202876-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2012-06-19 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029605-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS FYN, ABL2, LCK LCK 3/4885LYN 12/4885SRC 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.